Stay updated on Reslizumab in EGPA: Clinical Trial
Sign up to get notified when there's something new on the Reslizumab in EGPA: Clinical Trial page.

Latest updates to the Reslizumab in EGPA: Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2. This is a minor metadata change and does not affect study content or results.SummaryDifference0.1%

- Check19 days agoChange DetectedThe only change is a version update from v3.4.0 to v3.4.1; no study content, eligibility criteria, or results were affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check33 days agoChange DetectedAdded UI controls for Show glossary and Hide glossary, and updated the page revision label to Revision: v3.4.0. Minor capitalization changes to 'Last Update Submitted' and 'No FEAR Act' text were applied.SummaryDifference0.4%

- Check41 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed; this seems to be metadata/versioning information rather than a substantive change to content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check69 days agoChange DetectedAdded a dedicated 'Locations' section featuring the Colorado site. Removed the old 'Colorado Locations' entry and the 'HHS Vulnerability Disclosure' link from the footer.SummaryDifference0.2%

- Check91 days agoChange DetectedThe PubMed publications note has been updated to say that publications are automatically filled from PubMed and may not be about the study. The revision label has been updated to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Reslizumab in EGPA: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reslizumab in EGPA: Clinical Trial page.